Indifference, not innovation - Senior Scientist bei Merck: Mitarbeiterbewertung

2,0
2. Juli 2021
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Merck offers opportunities to work on independent projects and publication is highly encouraged. This is particularly straightforward in the chemistry department, which is very well resourced.

Kontras

The culture at Merck has become one of indifference to innovative bioscience, which is reflected in the mood of employees and management alike: low enthusiasm for the science and apathy toward influencing the next generation of therapeutics. It was discouraging to see great colleagues’ talent go unused and their drive to impact patients be neglected. Conversations in the labs rarely touched on scientific topics as people bided their time before the commute home, meetings focused on box-checking exercises to fulfill year-end goals, and managers closed their office doors to read the news and trade stocks. Over the course of 2018-2021, many experienced colleagues departed the company, leaving those content with the status quo and ensconcing a culture of indifference.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle